A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Inclusion Criteria:

- Signed informed consent or assent (for subjects under legal adult age)

- Completed Week 12 visit of either DRM01B-ACN03 or DRM01B-ACN04 studies.

- Willing to comply with the protocol. Subjects under legal adult age will be assessed
by the investigator as to their ability to comply with the protocol

- Willing to refrain from using any treatments on the face for acne vulgaris, other than
the investigational product, including topical or systemic antibiotics.

Exclusion Criteria:

- Abnormal clinically significant findings on physical exam, vital signs or ECG at Week
12 visit of either the DRM01-ACN03 or DMR01-ACN04 studies that would make further
treatment with Olumacostat Glasaretil Gel contraindicated, as determined by the
Investigator

- Any other condition which, in the judgment of the investigator, would put the subject
at unacceptable risk for participation in the study